Walleye Capital’s Ibere Pharmaceuticals IBER Stock Holding History

Walleye Capital’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-110,048	Closed	-$1.11M	–	4613
2022 Q4	$1.11M	Hold	110,048	–	–	0.02%	937
2022 Q3	$1.09M	Hold	110,048	–	–	0.02%	913
2022 Q2	$1.08M	Hold	110,048	–	–	0.03%	609
2022 Q1	$1.08M	Buy	110,048 +927	+0.8%	+$9.03K	0.03%	603
2021 Q4	$1.06M	Buy	+109,121	New	+$1.06M	0.03%	557

Walleye Capital's IBER Position: Q1 2023 in Review

Walleye Capital sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 110,048 shares — an estimated $1.11M sold.

Walleye Capital first reported a position in IBER in Q4 2021 and held it in 5 quarters. The position peaked at $1.11M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Walleye Capital reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Walleye Capital sold 110,048 Ibere Pharmaceuticals shares in Q1 2023, an estimated $1.11M.
Walleye Capital first reported a position in Ibere Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Walleye Capital's Ibere Pharmaceuticals position peaked at $1.11M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.